-
Published 12/14/2024
Pandey KS, Giles K, Balashov K, Macdonell R, Windsheimer J, Martinez M, Božin I, Raynaud S, Scaramozza M, Mokliatchouk O, Sun Z, Belviso N, Sato Y, Lin X, Okai A. Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study. Neurol Ther. 2025 Feb; 14(1):243-260. PMID: 39673658.
-
Published 11/21/2024
Mao-Draayer Y, Bar-Or A, Balashov K, Foley J, Smoot K, Longbrake EE, Robertson D, Mendoza JP, Lewin JB, Everage N, Božin I, Lyons J, Mokliatchouk O, Bame E, Giuliani F. Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients. Adv Ther. 2025 Jan; 42(1):395-412. PMID: 39570545.
-
Published 10/21/2022
Yadav SK, Ito N, Mindur JE, Kumar H, Youssef M, Suresh S, Kulkarni R, Rosario Y, Balashov KE, Dhib-Jalbut S, Ito K. Fecal Lcn-2 level is a sensitive biological indicator for gut dysbiosis and intestinal inflammation in multiple sclerosis. Front Immunol. 2022; 13:1015372. PMID: 36341389.
-
Published 5/28/2020
Balashov K, Dhib-Jalbut S, Rybinnik I. Fibrinolysis induced clinical improvement in a patient with multiple sclerosis exacerbation. Mult Scler Relat Disord. 2020 Aug; 43:102225. PMID: 32505025.
-
Published 10/1/2016
Balashov K. Imaging of Central Nervous System Demyelinating Disorders. Continuum (Minneap Minn). 2016 Oct; 22(5, Neuroimaging):1613-1635. PMID: 27740991.